Report
Anna Baran
EUR 100.00 For Business Accounts Only

No Major Surprises in PRA Health's Fourth Quarter, but Bookings Growth Seems To Be Decelerating

PRA Health reported fourth-quarter revenue of about $730 million, slightly below our expectations and up 4.2% from last year, excluding the impact from new accounting standards, foreign exchange rates, and reimbursed revenue. Operating expenses were in line with our expectations, and slightly lower-than-expected tax expense and transaction-related costs led to fourth-quarter net income above our expectations at $71 million. On an adjusted basis, operating margin improved nicely by 100 basis poin...
Underlying
PRA Health Sciences Inc.

PRA Health Sciences is a contract research organization engaged in providing outsourced clinical development and data solution services to the biotechnology and pharmaceutical industries. The company has two reportable segments: Clinical Research, which performs a range of services across the spectrum of clinical development programs, from the filing of investigational new drug applications and similar regulatory applications to conducting all phases of clinical trials; and Data Solutions, which provides data, analytics, technology, and consulting solutions to the life sciences market including market intelligence services, consulting and services, and apps and technology.

Provider
Morningstar
Morningstar

Morningstar, Inc. is a leading provider of independent investment research in North America, Europe, Australia, and Asia. The company offer an extensive line of products and services for individual investors, financial advisors, asset managers, and retirement plan providers and sponsors.

Morningstar provides data on approximately 530,000 investment offerings, including stocks, mutual funds, and similar vehicles, along with real-time global market data on more than 18 million equities, indexes, futures, options, commodities, and precious metals, in addition to foreign exchange and Treasury markets. Morningstar also offers investment management services through its investment advisory subsidiaries and had approximately $185 billion in assets under advisement and management as of June 30, 2016.

We have operations in 27 countries.

Analysts
Anna Baran

Other Reports on these Companies

PRA Health Sciences利用Synoma率先实现临床试验患者与其现实数据相连接

PRA Health Sciences利用Synoma率先实现临床试验患者与其现实数据相连接 制药、生物科技和其他研究发起方现在可以将他们的临床研究与纵向现实数据连接,从而加快药物开发,并与《21世纪治愈法案》保持一致。 北卡罗来纳州罗利市, May 14, 2021 (GLOBE NEWSWIRE) -- PRA Health Sciences, Inc. (NASDAQ: PRAH)今天宣布了一项采用Synoma®的创新标记化解决方案。Synoma是PRA的一项专有技术,可为药物开发提供更有力的证据。凭借PRA的解决方案,在隐私当先的前提下将临床试验数据和辅助数据集相连接成为可能。今天,三家大型制药公司以及其他几家不同规模的制药和生物科技公司正在使用Synoma,在其药物开发组合中建立数据链接并开展分析。 “数十种来源提供了各种类型的数据。然而,其中缺失的一环是将临床试验数据与现实数据得到的洞察相联系的能力。填补这项空白,可让研究人员能够以保护隐私的方式了解一项研究之外和之后发生的相关情况,” PRA Health Sciences执行副总裁兼首席科学官Kent Thoelke介绍说, “研究人员可以利用标记化和链接方法,随着时间的推移收集药物安全性和有效性方面的最佳洞察。” PRA可以与多种信息源的各种标记合作,从而能够纳入更广泛的现实数据集,并且按照《21...

Other Reports from Morningstar

ResearchPool Subscriptions

Get the most out of your insights

Get in touch